To investigate the Maximum Tolerated Dose(Phase 1) 12 month [clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301]

To investigate the Maximum Tolerated Dose(Phase 1) 12 month [clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301]

Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI [clinicaltrials:NCT01602952]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To investigate the Maximum Tolerated Dose(Phase 1) 12 month [clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301]

Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301
Bio2RDF identifier
74dd850a3dd42345fe3494fe72ced301
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301
measure [clinicaltrials_vocabulary:measure]
To investigate the Maximum Tolerated Dose(Phase 1)
time frame [clinicaltrials_vocabulary:time-frame]
description
Radotinib will be given orally ...... tion of Radotinib stops rising
identifier
clinicaltrials_resource:74dd850a3dd42345fe3494fe72ced301
title
To investigate the Maximum Tolerated Dose(Phase 1) 12 month
@en
inDataset
type
label
To investigate the Maximum Tol ...... d850a3dd42345fe3494fe72ced301]
@en